Colorectal Cancer Clinical Trials

Showing 1-20 of 1,434 trials

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

NCT07281768

The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-positive, T3 node-negative, T3 node-positive).

Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins66 participantsStarted Apr 2026

Baltimore, Maryland, United States

Active Not RecruitingPhase 2

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

NCT04751370

This phase II trial investigates the effect of nivolumab and ipilimumab when given together with short-course radiation therapy in treating patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may kill more cancer cells.

Locally Advanced Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8

National Cancer Institute (NCI)31 participantsStarted Feb 2022

Mobile, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +213 more locations

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Related Searches

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Adjuvant Low Dose Aspirin in Colorectal Cancer

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI